Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Minocycline + tretinoin is a combination therapy commonly used in the treatment of moderate to severe acne vulgaris. Minocycline is an oral tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, providing antibacterial and anti-inflammatory effects. Tretinoin is a topical retinoid (vitamin A derivative) that promotes epidermal cell turnover, reduces comedone formation, and modulates inflammation by activating nuclear retinoic acid receptors (RARs and RXRs). The combination targets both inflammatory and non-inflammatory acne lesions: minocycline addresses the bacterial/inflammatory component while tretinoin improves abnormal keratinization and reduces comedones[2][5][8]. This regimen has demonstrated significant efficacy in reducing lesion counts in clinical studies[2]. However, concurrent use increases the risk of pseudotumor cerebri (benign intracranial hypertension), a rare but serious adverse effect[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on minocycline + tretinoin.